Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab.

ABSTRACT:

Importance

B-cell-depleting monoclonal antibodies are widely used for treatment of multiple sclerosis but are associated with an impaired response to vaccines.

Objective

To identify factors associated with a favorable vaccine response to tozinameran.

Design, setting, and participants

This prospective cohort study was conducted in a specialized multiple sclerosis clinic at a university hospital from January 21 to December 1, 2021. Of 75 patients evaluated for participation who received a diagnosis of multiple sclerosis with planned or ongoing treatment with rituximab, 69 were included in the study, and data from 67 were analyzed.

Exposures

Sex, age, number of previous rituximab infusions, accumulated dose of rituximab, previous COVID-19 infection, time since las

SUBMITTER: Tolf A 

PROVIDER: S-EPMC9096596 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature